Linvoseltamab is a BCMA-targeting bispecific antibody used to treat relapsed/refractory multiple myeloma. The FDA plans to review the therapy for approval on August 22nd, 2024. 

Linvoseltamab Clinical Trials (July 2024)

NCT05730036: Phase 3 Study of Linvoseltamab for Relapsed/Refractory Myeloma 

• This Phase III (3) study is for relapsed/refractory myeloma patients. 
• The aim of this study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone (EPd).

NCT05828511: Linvoseltamab Treatment in Untreated Active Myeloma Patients

• The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible).
• The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM.
• Status: Actively Recruiting (as of July 2024)

NCT06292780: Linvoseltamab Treatment in Relapsed/Refractory Amyloidosis Patients 

• This Phase I (1) study is for relapsed/refractory AL amyloidosis patients. 
• This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again.
• Findings will help determine correct dosing, efficacy against amyloidosis organ damage, side effect profiling and more. 
• Status: Actively Recruiting (as of July 2024)

For more or updated information on these clinical trials, check out our HealthTree Myeloma Clinical Trial Finder. 

Learn more about linvoseltamab

Interview filmed at EHA, in June 2024.